Alector, Inc. Appoints Neil Berkley as Chief Financial Officer

Alector appoints Neil Berkley as CFO, enhancing leadership in neurodegeneration therapy development amid important company advancements.

Quiver AI Summary

Alector, Inc., a biotechnology company focused on therapies for neurodegeneration, announced the appointment of Neil Berkley as Chief Financial Officer, effective December 10, 2025. Berkley, who has been with the company since March 2024 and served as both Chief Business Officer and Interim CFO, will continue to hold his role as CBO. Alector's CEO, Arnon Rosenthal, praised Berkley's leadership and deep understanding of the company's science and business, which equips him well for the CFO position during a critical time in the company's development. With over 20 years of experience in biotech and corporate strategy, Berkley has played a significant role in advancing Alector's strategic goals and partnerships, aiming to enhance the delivery and efficacy of therapies for diseases like Alzheimer's and Parkinson's.

Potential Positives

Neil Berkley's appointment as CFO reflects confidence in his leadership and experience, which could enhance strategic decision-making and financial stability for Alector.
Berkley's background in corporate strategy, finance, and operations may support the company’s growth and help advance its promising pipeline of therapies for neurodegenerative diseases.
The focus on developing the ABC-enabled programs suggests a strategic innovation that may improve drug delivery and patient outcomes, potentially positioning Alector favorably in the competitive biotech market.
The continuity of leadership with Berkley serving as both CFO and CBO may facilitate cohesive strategy execution during a critical period for the company's development efforts.

Potential Negatives

Neil Berkley has taken on the role of CFO amidst a critical period for the company, which could indicate instability or a lack of established leadership in this key position.
The dual role of CBO and CFO may raise concerns regarding potential conflicts of interest and workload management, especially as Alector advances important initiatives.

FAQ

Who has been appointed CFO of Alector?

Neil Berkley has been appointed as CFO of Alector, effective December 10, 2025.

What experience does Neil Berkley bring to Alector?

Neil Berkley has over two decades of experience in corporate strategy, finance, and operations in the biotech industry.

What is Alector's mission?

Alector aims to develop therapies to counteract the progression of neurodegenerative diseases.

What technologies does Alector utilize in its research?

Alector leverages genetics, immunology, and neuroscience to develop its therapeutic programs.

What is the Alector Brain Carrier (ABC)?

The Alector Brain Carrier is a proprietary platform aimed at enhancing therapeutic delivery to the brain.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$ALEC Insider Trading Activity

$ALEC insiders have traded $ALEC stock on the open market 11 times in the past 6 months. Of those trades, 0 have been purchases and 11 have been sales.

Here’s a breakdown of recent trading of $ALEC stock by insiders over the last 6 months:

ARNON ROSENTHAL (Chief Executive Officer) has made 0 purchases and 2 sales selling 155,909 shares for an estimated $245,566.
SARA KENKARE-MITRA (President and Head of R&D) has made 0 purchases and 2 sales selling 65,325 shares for an estimated $105,692.
NEIL LINDSAY BERKLEY (Chief Bus Ofcr & Interim CFO) has made 0 purchases and 2 sales selling 53,103 shares for an estimated $81,271.
PAULA HAMMOND sold 14,000 shares for an estimated $32,998
GRACE WONG-SARAD (Principal Accounting Officer) has made 0 purchases and 3 sales selling 18,719 shares for an estimated $29,525.
KRISTINE YAFFE sold 1,000 shares for an estimated $1,440

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$ALEC Hedge Fund Activity

We have seen 73 institutional investors add shares of $ALEC stock to their portfolio, and 69 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

RA CAPITAL MANAGEMENT, L.P. removed 9,695,228 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $13,573,319
PRICE T ROWE ASSOCIATES INC /MD/ removed 2,690,232 shares (-55.2%) from their portfolio in Q3 2025, for an estimated $7,963,086
ADAR1 CAPITAL MANAGEMENT, LLC removed 1,723,526 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $5,101,636
683 CAPITAL MANAGEMENT, LLC added 1,000,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $2,960,000
SIO CAPITAL MANAGEMENT, LLC removed 845,531 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $2,502,771
FRANKLIN RESOURCES INC removed 834,270 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $1,167,978
BLACKROCK, INC. removed 775,607 shares (-9.7%) from their portfolio in Q3 2025, for an estimated $2,295,796

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$ALEC Analyst Ratings

Wall Street analysts have issued reports on $ALEC in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

HC Wainwright & Co. issued a "Buy" rating on 10/22/2025
Mizuho issued a "Outperform" rating on 07/28/2025

To track analyst ratings and price targets for $ALEC, check out Quiver Quantitative's $ALEC forecast page.

$ALEC Price Targets

Multiple analysts have issued price targets for $ALEC recently. We have seen 3 analysts offer price targets for $ALEC in the last 6 months, with a median target of $5.0.

Here are some recent targets:

Andrew Fein from HC Wainwright & Co. set a target price of $5.0 on 10/22/2025
Thomas Shrader from BTIG set a target price of $5.0 on 09/25/2025
Graig Suvannavejh from Mizuho set a target price of $3.5 on 07/28/2025

Full Release

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that Neil Berkley, who has served as Alector’s Chief Business Officer (CBO) since March 2024, and CBO and Interim Chief Financial Officer (CFO) since June 2025, has been appointed CFO, effective December 10, 2025. Mr. Berkley will continue to serve as CBO.

“Neil has demonstrated exceptional leadership, judgment, strategic insight, and an unwavering commitment to Alector’s mission,” said Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector. “His deep understanding of our science and business drivers—combined with his operational and financial acumen—makes him uniquely suited to assume the CFO role as we advance through an important period for the company.”

Mr. Berkley is an accomplished biotech executive with more than two decades of experience leading corporate strategy, finance, business development, and operations across both early- and late-stage companies. He brings broad experience across large pharmaceutical, midsize biotechnology, and emerging biotech companies, and has supported a wide range of strategic and transactional partnerships throughout his career. Since joining Alector in 2024, he has played a key role in advancing the company’s strategic priorities, strengthening partnerships, and supporting key value-creation initiatives across the organization. He also brings experience in financing and fundraising, investor engagement, and corporate development, along with a background that includes founding two companies and serving on the boards of multiple biotech organizations.

“I’m honored to serve Alector in this capacity,” said Berkley. “It is a privilege to work with such a talented team dedicated to advancing transformative therapies to patients with neurodegenerative diseases. I look forward to continuing to support the company’s scientific and corporate priorities, including the advancement of our promising pipeline and the ongoing development of our ABC-enabled programs.”

About Alector
Alector is a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of programs that aim to remove toxic proteins, replace missing proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector’s product candidates seek to treat a range of indications, such as Alzheimer’s disease, Parkinson's disease, and frontotemporal dementia. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being selectively applied to its preclinical and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit www.alector.com .

Alector Contacts:
Argot Partners (media)
David Rosen
(212) 600-1494
[email protected]

Argot Partners (investors)
Laura Perry
(212) 600-1902
[email protected]